Inhaled corticosteroids and mortality in COPD
- PMID: 16963657
- DOI: 10.1378/chest.130.3.640
Inhaled corticosteroids and mortality in COPD
Abstract
Study objectives: To assess the influence of inhaled corticosteroids (ICSs) on mortality in COPD patients, which is currently a controversial topic.
Setting: Manitoba Health maintains a population-wide research database that includes pharmaceutical information.
Design and patients: We examined mortality in people 90 to 365 days after hospital discharge for COPD, comparing those persons who received inhaled steroids within 90 days of hospital discharge with those who did not. Cox proportional hazards models were used with adjustments for other respiratory drugs, comorbidities, and physician visits before and after hospital discharge. We also compared mortality in patients who received inhaled steroids with those who received other respiratory drugs, but not inhaled steroids, and those who received neither. Using nested case control analysis, we examined the time of receipt of inhaled steroids in relation to fatal events.
Results: In people > 65 years of age, inhaled steroids were associated with a 25% reduction in mortality between 90 and 365 days after hospital discharge, while mortality increased with bronchodilator use, physician visits, age, and comorbidities. The exclusion of people who had also received a diagnosis of asthma or had received inhaled steroids before hospitalization did not change the result. Inhaled steroids were associated with an even larger mortality reduction in people aged 35 to 64 years. People who received bronchodilators but no steroids had higher mortality than people who received no bronchodilators or received both bronchodilators and inhaled steroids. The reduction in all-cause mortality was largely due to the decreased number of cardiovascular deaths. The receipt of inhaled steroids within 30 days of death was protective, but this was not the case for greater time intervals.
Conclusions: Therapy with ICSs reduced mortality in COPD patients; the effect was particularly notable for cardiovascular death and was short term in that it was dependent on recent exposure.
Comment in
-
Cooling the fire within: inhaled corticosteroids and cardiovascular mortality in COPD.Chest. 2006 Sep;130(3):629-31. doi: 10.1378/chest.130.3.629. Chest. 2006. PMID: 16963650 No abstract available.
-
Inhaled corticosteroids and mortality in COPD.Chest. 2007 Mar;131(3):939; author reply 940. doi: 10.1378/chest.06-2473. Chest. 2007. PMID: 17356119 No abstract available.
-
Inhaled corticosteroids and mortality in COPD.Chest. 2007 Mar;131(3):939; author reply 940. Chest. 2007. PMID: 17380589 No abstract available.
Similar articles
-
Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease.Ann Pharmacother. 2010 Apr;44(4):613-22. doi: 10.1345/aph.1M243. Epub 2010 Mar 16. Ann Pharmacother. 2010. PMID: 20233915
-
Incidence, Predictors, and Clinical Implications of Discontinuing Therapy with Inhaled Long-Acting Bronchodilators among Patients with Chronic Obstructive Pulmonary Disease.COPD. 2016 Oct;13(5):540-6. doi: 10.3109/15412555.2016.1141877. Epub 2016 Mar 2. COPD. 2016. PMID: 26934569
-
Effect of outpatient therapy with inhaled corticosteroids on decreasing in-hospital mortality from pneumonia in patients with COPD.Int J Chron Obstruct Pulmon Dis. 2016 Jun 23;11:1403-11. doi: 10.2147/COPD.S107985. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27382276 Free PMC article.
-
Inhaled corticosteroids for chronic obstructive pulmonary disease.Expert Opin Pharmacother. 2013 Dec;14(18):2489-99. doi: 10.1517/14656566.2013.848856. Epub 2013 Oct 21. Expert Opin Pharmacother. 2013. PMID: 24138334 Review.
-
Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease.Proc Am Thorac Soc. 2006 Sep;3(7):624-9. doi: 10.1513/pats.200603-096SS. Proc Am Thorac Soc. 2006. PMID: 16963545 Review.
Cited by
-
Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis?Drugs. 2007;67(7):965-74. doi: 10.2165/00003495-200767070-00002. Drugs. 2007. PMID: 17488142 Review.
-
The validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease.BMC Health Serv Res. 2011 Feb 16;11:37. doi: 10.1186/1472-6963-11-37. BMC Health Serv Res. 2011. PMID: 21324188 Free PMC article.
-
Risk of Cardiovascular Events Associated with Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis.Can Respir J. 2018 Jul 15;2018:7097540. doi: 10.1155/2018/7097540. eCollection 2018. Can Respir J. 2018. PMID: 30123392 Free PMC article. Review.
-
A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids.Br J Pharmacol. 2008 Mar;153(6):1090-104. doi: 10.1038/sj.bjp.0707627. Epub 2007 Dec 10. Br J Pharmacol. 2008. PMID: 18071293 Free PMC article. Review.
-
Mechanisms of atherothrombosis in chronic obstructive pulmonary disease.Int J Chron Obstruct Pulmon Dis. 2008;3(1):89-96. doi: 10.2147/copd.s1401. Int J Chron Obstruct Pulmon Dis. 2008. PMID: 18488431 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical